keyword
MENU ▼
Read by QxMD icon Read
search

Schizophrenia cbd

keyword
https://www.readbyqxmd.com/read/29794254/cannabidiol-effects-on-prepulse-inhibition-in-nonhuman-primates
#1
Patricia G Saletti, Carlos Tomaz
Prepulse inhibition (PPI) of acoustic startle reflex is a well-established behavior paradigm to measure sensorimotor gating deficits. PPI is disrupted in several neuropsychiatric disorders, including schizophrenia. PPI tests can be used to screen new drugs for treatment of such disorders. In this review, we discuss how PPI paradigm can help in screening the therapeutic effects of cannabidiol (CBD). We look into recent literature about CBD effects on PPI response in animal models, especially in nonhuman primates...
May 24, 2018: Reviews in the Neurosciences
https://www.readbyqxmd.com/read/29789034/pharmacological-properties-of-cannabidiol-in-the-treatment-of-psychiatric-disorders-a-critical-overview
#2
G M Mandolini, M Lazzaretti, A Pigoni, L Oldani, G Delvecchio, P Brambilla
Cannabidiol (CBD) represents a new promising drug due to a wide spectrum of pharmacological actions. In order to relate CBD clinical efficacy to its pharmacological mechanisms of action, we performed a bibliographic search on PUBMED about all clinical studies investigating the use of CBD as a treatment of psychiatric symptoms. Findings to date suggest that (a) CBD may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) CBD administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1A receptor agonism; (c) CBD may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of CBD still lack significant results in psychiatric disorders...
May 23, 2018: Epidemiology and Psychiatric Sciences
https://www.readbyqxmd.com/read/29770251/review-of-the-neurological-benefits-of-phytocannabinoids
#3
REVIEW
Joseph Maroon, Jeff Bost
Background: Numerous physical, psychological, and emotional benefits have been attributed to marijuana since its first reported use in 2,600 BC in a Chinese pharmacopoeia. The phytocannabinoids, cannabidiol (CBD), and delta-9-tetrahydrocannabinol (Δ9-THC) are the most studied extracts from cannabis sativa subspecies hemp and marijuana. CBD and Δ9-THC interact uniquely with the endocannabinoid system (ECS). Through direct and indirect actions, intrinsic endocannabinoids and plant-based phytocannabinoids modulate and influence a variety of physiological systems influenced by the ECS...
2018: Surgical Neurology International
https://www.readbyqxmd.com/read/29682609/prolonged-cannabidiol-treatment-effects-on-hippocampal-subfield-volumes-in-current-cannabis-users
#4
Camilla Beale, Samantha J Broyd, Yann Chye, Chao Suo, Mark Schira, Peter Galettis, Jennifer H Martin, Murat Yücel, Nadia Solowij
Introduction: Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While adverse impacts of cannabis use are generally attributed to Δ9 -tetrahydrocannabinol, emerging naturalistic evidence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis use, including protection from hippocampal volume loss. This study examined whether prolonged administration of CBD to regular cannabis users within the community could reverse or reduce the characteristic hippocampal harms associated with chronic cannabis use...
2018: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/29619533/the-effects-of-cannabidiol-cbd-on-cognition-and-symptoms-in-outpatients-with-chronic-schizophrenia-a-randomized-placebo-controlled-trial
#5
Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza, Mohini Ranganathan
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). OBJECTIVE: This study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial. METHODS: This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia...
April 5, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29241357/cannabidiol-cbd-as-an-adjunctive-therapy-in-schizophrenia-a-multicenter-randomized-controlled-trial
#6
Philip McGuire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. METHOD: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S)...
March 1, 2018: American Journal of Psychiatry
https://www.readbyqxmd.com/read/29098186/chronic-adolescent-%C3%AE-9-tetrahydrocannabinol-treatment-of-male-mice-leads-to-long-term-cognitive-and-behavioral-dysfunction-which-are-prevented-by-concurrent-cannabidiol-treatment
#7
Michelle Murphy, Sierra Mills, Joanna Winstone, Emma Leishman, Jim Wager-Miller, Heather Bradshaw, Ken Mackie
Introduction: The high prevalence of adolescent cannabis use, the association between this use and later psychiatric disease, and increased access to high-potency cannabis highlight the need for a better understanding of the long-term effects of adolescent cannabis use on cognitive and behavioral outcomes. Furthermore, increasing Δ9 -tetrahydrocannabinol (THC) in high-potency cannabis is accompanied by a decrease in cannabidiol (CBD), thus an understanding of the interactions between CBD and THC in the neurodevelopmental effects of THC is also important...
2017: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/29083450/the-potential-of-cannabidiol-treatment-for-cannabis-users-with-recent-onset-psychosis
#8
Britta Hahn
A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to ∆9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective effects...
January 13, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29063964/phytocannabinoids-modulate-emotional-memory-processing-through-interactions-with-the-ventral-hippocampus-and-mesolimbic-dopamine-system-implications-for-neuropsychiatric-pathology
#9
REVIEW
Roger Hudson, Walter Rushlow, Steven R Laviolette
Growing clinical and preclinical evidence suggests a potential role for the phytocannabinoid cannabidiol (CBD) as a pharmacotherapy for various neuropsychiatric disorders. In contrast, delta-9-tetrahydrocannabinol (THC), the primary psychoactive component in cannabis, is associated with acute and neurodevelopmental propsychotic side effects through its interaction with central cannabinoid type 1 receptors (CB1Rs). CB1R stimulation in the ventral hippocampus (VHipp) potentiates affective memory formation through inputs to the mesolimbic dopamine (DA) system, thereby altering emotional salience attribution...
February 2018: Psychopharmacology
https://www.readbyqxmd.com/read/28680405/cannabinoids-and-vanilloids-in-schizophrenia-neurophysiological-evidence-and-directions-for-basic-research
#10
REVIEW
Rafael N Ruggiero, Matheus T Rossignoli, Jana B De Ross, Jaime E C Hallak, Joao P Leite, Lezio S Bueno-Junior
Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to map fundamental mechanisms of sensorimotor gating, hyperlocomotion, social interaction, and underlying monoaminergic, glutamatergic, and GABAergic disturbances. These strategies will require, however, a greater use of neurophysiological tools to better inform clinical research...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28634109/cannabis-associated-psychosis-neural-substrate-and-clinical-impact
#11
REVIEW
R M Murray, A Englund, A Abi-Dargham, D A Lewis, M Di Forti, C Davies, M Sherif, P McGuire, D C D'Souza
Prospective epidemiological studies have consistently demonstrated that cannabis use is associated with an increased subsequent risk of both psychotic symptoms and schizophrenia-like psychoses. Early onset of use, daily use of high-potency cannabis, and synthetic cannabinoids carry the greatest risk. The risk-increasing effects are not explained by shared genetic predisposition between schizophrenia and cannabis use. Experimental studies in healthy humans show that cannabis and its active ingredient, delta-9-tetrahydrocannabinol (THC), can produce transient, dose-dependent, psychotic symptoms, as well as an array of psychosis-relevant behavioral, cognitive and psychophysiological effects; the psychotogenic effects can be ameliorated by cannabidiol (CBD)...
September 15, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28588483/plastic-and-neuroprotective-mechanisms-involved-in-the-therapeutic-effects-of-cannabidiol-in-psychiatric-disorders
#12
REVIEW
Alline C Campos, Manoela V Fogaça, Franciele F Scarante, Sâmia R L Joca, Amanda J Sales, Felipe V Gomes, Andreza B Sonego, Naielly S Rodrigues, Ismael Galve-Roperh, Francisco S Guimarães
Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28584843/ruptured-dissecting-intramural-duodenal-hematoma-following-endoscopic-retrograde-cholangiopancreatography
#13
Eric Weiss, Madeline Tadley, Pak S Leung, Mark Kaplan
A 34-year-old woman with schizophrenia developed abdominal pain. Ultrasound demonstrated cholelithiasis and a dilated biliary tree. The patient underwent endoscopic retrograde cholangiopancreatography (ERCP), sphincterotomy, and extraction of gallstones from the common bile duct. She developed post-procedure fever, tachycardia, and abdominal pain and was taken to the operating room for urgent cholecystectomy with intraoperative cholangiogram. At laparotomy, an intramural dissecting duodenal hematoma was discovered, which extended the length of the duodenum and ruptured...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/28289391/cannabidiol-affects-mk-801-induced-changes-in-the-ppi-learned-response-of-capuchin-monkeys-sapajus-spp
#14
Patricia G Saletti, Rafael S Maior, Marilia Barros, Hisao Nishijo, Carlos Tomaz
There are several lines of evidence indicating a possible therapeutic action of cannabidiol (CBD) in schizophrenia treatment. Studies with rodents have demonstrated that CBD reverses MK-801 effects in prepulse inhibition (PPI) disruption, which may indicate that CBD acts by improving sensorimotor gating deficits. In the present study, we investigated the effects of CBD on a PPI learned response of capuchin monkeys (Sapajus spp.). A total of seven monkeys were employed in this study. In Experiment 1, we evaluated the CBD (doses of 15, 30, 60 mg/kg, i...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28230072/improved-social-interaction-recognition-and-working-memory-with-cannabidiol-treatment-in-a-prenatal-infection-poly-i-c-rat-model
#15
Ashleigh L Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang, Katrina Weston-Green
Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD treatment on cognition and social interaction...
June 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28185872/neuronal-and-molecular-effects-of-cannabidiol-on-the-mesolimbic-dopamine-system-implications-for-novel-schizophrenia-treatments
#16
REVIEW
Justine Renard, Christopher Norris, Walter Rushlow, Steven R Laviolette
Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of cannabis, as a potential pharmacotherapy for various neuropsychiatric disorders. In contrast to delta-9-tetrahydrocannabinol (THC), which is associated with acute and neurodevelopmental pro-psychotic side-effects, CBD possesses no known psychoactive or dependence-producing properties. However, evidence has demonstrated that CBD strongly modulates the mesolimbic dopamine (DA) system and may possess promising anti-psychotic properties...
April 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/28112021/is-there-a-role-for-cannabidiol-in-psychiatry
#17
Julia Machado Khoury, Maila de Castro Lourenço das Neves, Marco Antônio Valente Roque, Daniela Alves de Brito Queiroz, André Augusto Corrêa de Freitas, Ângelo de Fátima, Fabrício A Moreira, Frederico Duarte Garcia
OBJECTIVES: Understanding whether cannabidiol (CBD) is useful and safe for the treatment of psychiatric disorders is essential to empower psychiatrists and patients to take good clinical decisions. Our aim was to conduct a systematic review regarding the benefits and adverse events (AEs) of CBD in the treatment of schizophrenia, psychotic disorders, anxiety disorders, depression, bipolar disorder and substance-use disorders. METHODS: We conducted a literature search in PubMed, Scielo, and Clinicaltrials...
February 20, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/27884751/a-systematic-review-of-the-effect-of-cannabidiol-on-cognitive-function-relevance-to-schizophrenia
#18
REVIEW
Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Green
BACKGROUND AND OBJECTIVES: Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored...
January 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27621706/evaluation-of-two-commercially-available-cannabidiol-formulations-for-use-in-electronic-cigarettes
#19
Michelle R Peace, Karen E Butler, Carl E Wolf, Justin L Poklis, Alphonse Poklis
Since 24 states and the District of Columbia have legalized marijuana in some form, suppliers of legal marijuana have developed Cannabis sativa products for use in electronic cigarettes (e-cigarettes). Personal battery powered vaporizers, or e-cigarettes, were developed to deliver a nicotine vapor such that smokers could simulate smoking tobacco without the inherent pathology of inhaled tobacco smoke. The liquid formulations used in these devices are comprised of an active ingredient such as nicotine mixed with vegetable glycerin (VG) and/or propylene glycol (PG) and flavorings...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27547037/tryptophan-metabolism-in-rat-liver-after-administration-of-tryptophan-kynurenine-metabolites-and-kynureninase-inhibitors
#20
Abdulla A-B Badawy, Samina Bano
Rat liver tryptophan (Trp), kynurenine pathway metabolites, and enzymes deduced from product/substrate ratios were assessed following acute and/or chronic administration of kynurenic acid (KA), 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), Trp, and the kynureni-nase inhibitors benserazide (BSZ) and carbidopa (CBD). KA activated Trp 2,3-dioxygenase (TDO), possibly by increasing liver 3-HAA, but inhibited kynurenine aminotransferase (KAT) and kynureninase activities with 3-HK as substrate. 3-HK inhibited kynureninase activity from 3-HK...
2016: International Journal of Tryptophan Research: IJTR
keyword
keyword
30258
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"